And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We look forward to another installment in our “Let’s-see-them-before-they-die” concert series, organize our library, and hang with our short person. And what about you? This remains a lovely time to enjoy the great outdoors. You could hunt for apples or pumpkins. Look ahead to a winter getaway. Or check to see how much health insurance you will have next year. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

Avanir Pharmaceuticals (AVNR) is raking in hundreds of millions of dollars a year by aggressively targeting elderly nursing home residents for whom its Nuedextra pill may be unnecessary or even unsafe, CNN reports. The drug is approved to treat a disorder marked by sudden and uncontrollable laughing or crying, but not extensively studied in elderly patients. Since 2012, more than half of all Nuedexta pills have gone to long-term care facilities.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • As a frequent nursing home visitor what I’ve witnessed is uncontrollable staccato bursts of anger from the relatives who visit once a year from Florida and stay long enough to find fault in virtually everything.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy